Navigation Links
VIA Pharmaceuticals Receives Delisting Notification From NASDAQ
Date:12/29/2009

SAN FRANCISCO, Dec. 29 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on December 29, 2009, it received a written notice from the listing qualifications staff of the NASDAQ Stock Market ("NASDAQ") informing the Company that trading of the Company's common stock would be suspended prior to the open of business on January 4, 2010 and that NASDAQ would initiate procedures to delist the Company's common stock. The Company had notified NASDAQ on December 23, 2009 that the Company would be unable to comply with NASDAQ listing rule 5550(b), which requires a minimum stockholders' equity requirement of $2.5 million, and NASDAQ listing rule 5605, which requires, among other things, that the Company's board of directors be comprised of at least a majority of independent directors and that the Company's audit committee be comprised of at least three independent directors. The Company does not intend to appeal the determination of NASDAQ with respect to the delisting of its common stock.

Following the delisting of the Company's common stock, the Company expects to be eligible for quotation on the OTC Bulletin Board ("OTCBB"), a regulated quotation service that displays real-time quotes, last sale prices and volume information in over-the-counter securities. However, quotation on the OTCBB will depend on whether one or more market makers will apply and be cleared by the Financial Industry Regulatory Authority to quote the Company's common stock on the OTCBB. No assurance can be provided that market makers currently making a market in the Company's common stock will continue to make a market in the Company's common stock or that the Company's common stock will continue to be eligi
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... -- QPID Health , a leader in clinical intelligence ... Boston and their first West Coast location ... Franklin Street in Boston , and will house ... Southern California office will be located ... meet the demands of customers nationwide.  Both new locations will ...
(Date:9/16/2014)... 16, 2014 Russia,s ... recent years. The Pharma 2020 Strategy provides incentives for ... both domestic and foreign markets. These trends, however, were ... and the following political and economic sanctions imposed on ... http://photos.prnewswire.com/prnh/20140916/706080) Russia responded ...
(Date:9/16/2014)... Mass. , Sept. 16, 2014  Decision Resources Group finds ... from $14 billion in 2013 to over $18.2 billion in 2023 ... , Germany , Italy ... and Japan . TNF-alpha inhibitors will ... in the RA market, but growth will be constrained and patient ...
Breaking Medicine Technology:QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 2Global Medicines for Russia 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 3
... Oct. 28 Thoratec Corporation (Nasdaq: THOR ... therapies to save, support and restore failing hearts, said ... 2010 increased 40 percent versus the third quarter of ... the third quarter and first nine months of 2010 ...
... Oct. 28 As part of its continued commitment ... CTIA–The Wireless Association® today announced that it is hosting ... World Forum for Medicine and International Trade Fair and ... mobile products, applications and network management solutions focused on ...
Cached Medicine Technology:Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 2Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 3Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 4Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 5Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 6Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 7Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 8Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 9Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 10Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 11Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 12Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 13Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 14Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 15Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 16CTIA-The Wireless Association® to Host First Wireless Health Pavilion at MEDICA 2010 World Forum for Medicine 2CTIA-The Wireless Association® to Host First Wireless Health Pavilion at MEDICA 2010 World Forum for Medicine 3
(Date:9/16/2014)... who tend to be on the heavy side. Researchers ... found that seven in every ten obese adults underestimate ... this mistake much less often. Mothers of overweight or ... as youngsters misjudge their obese mothers, size, says lead ... a study in the Journal of General Internal ...
(Date:9/16/2014)... the unwitting focus of some of Australia,s best fast ... their performance in competition, thanks to a new training ... Greenwood, from QUT,s Institute of Health and Biomedical Innovation, ... of Excellence for Applied Sport Science Research, has studied ... cricket, long jump, triple jump and pole vault and ...
(Date:9/16/2014)... that compared patient-reported outcomes of a broad set ... single fraction radiation therapy (SFRT) is equally as ... pain, function and quality of life are considered, ... Society for Radiation Oncology,s (ASTRO,s) 56th Annual Meeting. ... pain, function and degree of distress were similar ...
(Date:9/16/2014)... For patients with locally advanced pancreatic cancer, the ... may be a promising treatment option, ultimately allowing ... be an option, according to research presented today ... 56th Annual Meeting. , Surgery is the only ... adenocarcinoma (PDA), the most common type of pancreatic ...
(Date:9/16/2014)... 2014 -- While abnormalities in the adrenergic and ... are thought to play a role in the ... there has been no genetic evidence of this ... at Columbia University,s Mailman School of Public Health ... between the ADRB2 gene and childhood adversity. For ...
Breaking Medicine News(10 mins):Health News:Poor body size judgement can lead to increased tolerance of obesity 2Health News:Getting the jump on competitors: QUT study 2Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 2Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 3Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 4Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 2Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 3Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 4Health News:Evidence of genetic link to PTSD in soldiers exposed to childhood trauma 2Health News:Evidence of genetic link to PTSD in soldiers exposed to childhood trauma 3
... heart attack and stroke, U.S. officials say , , ... Prilosec with the popular blood thinner Plavix (clopidogrel) can ... at risk for heart attack or stroke, U.S. health ... recently submitted studies by the manufacturer of clopidogrel [Sanofi-Aventis ...
... Seattle Sutton,s Healthy Eating (SSHE) and the ... MCHC affiliated members with meal discounts for SSHE. , ... than 140 hospitals and health care organizations dedicated to improving ... care and in assisting its members in improving the delivery ...
... Mo. Until recently, scientists believed that, following a ... any lost function. After that, patients would be forced ... their remaining abilities. Although this belief has been refuted, ... the current health system is still not giving patients ...
... 17 As we approach Thanksgiving, "Black Friday" and the ... community to please remember the children and families whose lives ... recovery and survival. Among these diseases are leukemia and ... disease, hemophilia and other diseases. , Please take a few ...
... VEGAS, Nov. 17 Ultimat Vodka has recently announced plans ... eliminating world hunger, to help raise awareness and funds for ... "I,m Tired of...," (ITo) Ultimat has created unique wrist ... message "I,m Tired of Hunger." For each bracelet produced, Ultimat ...
... surgery, gunshot victim continues to show improvement , TUESDAY, ... the first facial transplant in the United States can ... her nose, according to a report from her surgeons. ... from the transplanted tissue have integrated with existing tissue, ...
Cached Medicine News:Health News:Heartburn Drugs Can Thwart Popular Blood Thinner 2Health News:Seattle Sutton's Healthy Eating Partners With Metropolitan Chicago Healthcare Council to Provide Discounts for Hospital Patients and Employees 2Health News:Seattle Sutton's Healthy Eating Partners With Metropolitan Chicago Healthcare Council to Provide Discounts for Hospital Patients and Employees 3Health News:Pushing the brain to find new pathways 2Health News:These Patients Need Your Help This Thanksgiving 2Health News:These Patients Need Your Help This Thanksgiving 3Health News:Ultimat Vodka Joins Fight Against Hunger 2Health News:Face Transplant Patient Can Smell, Taste, Breathe Normally 2Health News:Face Transplant Patient Can Smell, Taste, Breathe Normally 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: